GlassScriptPhysician profile
John S Pomichter
NPI 1588606800
$13,395.50
in general payments reported to CMS, 2019-2025
53 companies · $2,675 in 2025
The $2,675 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $629 · 2021: $895 · 2022: $2,228 · 2023: $2,866 · 2024: $2,710 · 2025: $2,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,076 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,076.02 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,027.96 | 2019-2025 | |
| Novo Nordisk INC | $1,129.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,082.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $923.72 | 2019-2025 | Jardiance |
| Pfizer INC. | $905.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $879.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $708.08 | 2019-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $637.48 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $607.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $440.80 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $418.83 | 2019-2025 | Trintellix |
| Allergan, INC. | $392.72 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.40 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $309.55 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $238.74 | 2023-2025 | Gemtesa |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pomichter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.